Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study

Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study

<p><strong>Background:</strong> Fibroblast growth factor 23 (FGF-23) is associated with a range of cardiovascular and non-cardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help con...

Descrición completa

Detalles Bibliográficos
Main Authors:	Donovan, K, Herrington, W, Haynes, R, Sardell, R, Baigent, C, Holmes, M, Staplin, N
Formato:	Journal article
Idioma:	English
Publicado:	American Society of Nephrology 2022

Títulos similares

Fibroblast growth factor-23 and risks of cardiovascular and non-cardiovascular diseases: a meta-analysis
por: Marthi, A, et al.
Publicado: (2018)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
por: Lamprea-Montealegre, J, et al.
Publicado: (2019)

Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study
por: Ying Liang, et al.
Publicado: (2021-07-01)

Corrigendum: Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study
por: Ying Liang, et al.
Publicado: (2021-11-01)

Fibroblast Growth Factor 23 and Cardiovascular Risk in Diabetes Patients—Cardiologists Be Aware
por: Anna Kurpas, et al.
Publicado: (2022-05-01)

Is fibroblast growth factor 23 a new cardiovascular risk marker in gestational diabetes?
por: Muhammed Kizilgul, et al.
Publicado: (2017-09-01)

Il Fibroblast Growth Factor-23 (FGF-23)
por: D. Rendina, et al.
Publicado: (2018-01-01)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
por: Storey, B, et al.
Publicado: (2017)

Fibroblast Growth Factor 23 and Incident Cardiovascular Disease and Mortality in Middle‐Aged Adults
por: Shejuti Paul, et al.
Publicado: (2021-08-01)

Evidence for the prevention and treatment of stroke in dialysis patients
por: Herrington, W, et al.
Publicado: (2014)

Fibroblast growth factor 23 and calcium‐phosphate metabolism in relation to cardiovascular risk factors in patients with type 1 diabetes
por: Stephanie Vermeulen, et al.
Publicado: (2024-06-01)

Serum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular risk
por: Klisic Aleksandra, et al.
Publicado: (2025-01-01)

Osteoprotegerin and fibroblast growth factor 23 in the development of cardiovascular events in chronic kidney disease
por: F U Dzgoeva, et al.
Publicado: (2014-06-01)

Physiological Actions of Fibroblast Growth Factor-23
por: Reinhold G. Erben
Publicado: (2018-05-01)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
por: Mayne, KM, et al.
Publicado: (2024)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
por: Mayne, K, et al.
Publicado: (2024)

Kidney disease trials for the 21st century: innovations in design and conduct
por: Herrington, W, et al.
Publicado: (2019)

PKC regulates the production of fibroblast growth factor 23 (FGF23).
por: Ludmilla Bär, et al.
Publicado: (2019-01-01)

Fibroblast Growth Factor-23 (FGF-23) e Sindrome Cardiorenale
por: Luca Di Lullo, et al.
Publicado: (2015-03-01)

A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway
por: Joseph Wang, et al.
Publicado: (2017-11-01)

The impact of growth differentiation factor 15 on the risk of cardiovascular diseases: two-sample Mendelian randomization study
por: Zhuo Wang, et al.
Publicado: (2020-10-01)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
por: Herrington, W, et al.
Publicado: (2016)

Role of Fibroblast Growth Factor 23 (FGF23) and αKlotho in Cancer
por: Franz Ewendt, et al.
Publicado: (2021-01-01)

The association of fibroblast growth factor 23 at mid-life and late-life with subsequent risk of cardiovascular disease: The Atherosclerosis Risk in Communities (ARIC) Study
por: Yasuyuki Honda, et al.
Publicado: (2022-01-01)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
por: Haynes, R, et al.
Publicado: (2018)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
por: Zhu, P, et al.
Publicado: (2020)

Causal Associations of Urate With Cardiovascular Risk Factors: Two-Sample Mendelian Randomization
por: Thitiya Lukkunaprasit, et al.
Publicado: (2021-07-01)

Role of fibroblast growth factor 23 in the development of cardiovascular diseases in patients with end-stage renal failure on programmed hemodialysis
por: F U Dzgoeva, et al.
Publicado: (2016-12-01)

Higher Fibroblast Growth Factor 23 Levels Are Causally Associated With Lower Bone Mineral Density of Heel and Femoral Neck: Evidence From Two-Sample Mendelian Randomization Analysis
por: Yue Wang, et al.
Publicado: (2020-09-01)

Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis
por: Menglu Liu, et al.
Publicado: (2022-11-01)

Fibroblast growth factor-23 rs7955866 polymorphism and risk of chronic kidney disease
por: Yaser Aly Ammar, et al.
Publicado: (2022-04-01)

Mendelian randomization study of the relevance of blood pressure to vascular mortality among 150,000 participants in the Mexico City Prospective Study
por: Turner, M, et al.
Publicado: (2023)

Fibroblast growth factor 23 levels before and after renal transplantation
por: Mohamed M El-khatib, et al.
Publicado: (2016-01-01)

Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery
por: Felix Hofer, et al.
Publicado: (2023-03-01)

Fibroblast growth factor-23 and cardiovascular disease among prevalent hemodialysis patients focusing on residual kidney function
por: Youn Kyung Kee, et al.
Publicado: (2023-07-01)

Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study
por: Robin Haring, et al.
Publicado: (2016-07-01)

Fibroblast Growth Factor-23 Helps Explain the Biphasic Cardiovascular Effects of Vitamin D in Chronic Kidney Disease
por: Peng Hu, Qiang Xuan, Bo Hu, Ling Lu, Jing Wang, Yuan Han Qin
Publicado: (2012-01-01)

Prognostic Importance of Fibroblast Growth Factor-23 in Dialysis Patients
por: Nilgül Akalin, et al.
Publicado: (2014-01-01)

Direct and indirect effects of fibroblast growth factor 23 on the heart
por: Toshiaki Nakano, et al.
Publicado: (2023-02-01)

Fibroblast Growth Factor-23—A Potential Uremic Toxin
por: Piotr Kuczera, et al.
Publicado: (2016-12-01)